SCHEDULE 13G: Investment Funds Disclose 9.9% Stake in Processa Pharmaceuticals

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 9.9% beneficial ownership stake in Processa Pharmaceuticals, Inc., totaling 2,663,078 shares.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed a Schedule 13G disclosing beneficial ownership of common stock in Processa Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 2,663,078 shares of Processa Pharmaceuticals, Inc. common stock.
• This ownership represents 9.9% of the class of securities.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
• The beneficially owned shares include 2,200,000 common shares and shares issuable upon the exercise of pre-funded and other warrants.
• The warrants are structured with a blocker provision, preventing exercise if it would result in beneficial ownership exceeding 9.99%.
• As of the completion of a recent offering, Processa Pharmaceuticals, Inc. had 26,194,356 shares outstanding (excluding shares underlying warrants), as indicated in their Prospectus filed on June 18, 2025.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial news about the issuer, Processa Pharmaceuticals, Inc., directly from the company itself. The sentiment is neutral as it simply reports a change in ownership structure.

Future Outlook

The document is a disclosure of current beneficial ownership and does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing indicates a significant investment by CVI Investments, Inc. and Heights Capital Management, Inc. in Processa Pharmaceuticals, Inc., a pharmaceutical company. Such an investment suggests a belief in the company's potential within the biotech or pharmaceutical sector, though the filing itself does not elaborate on the investment thesis or broader industry trends.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure of beneficial ownership. It does not contain performance metrics or operational results that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The 9.9% ownership stake is a significant position for an institutional investor, often indicating a strategic interest without triggering the more stringent reporting requirements of a 13D filing (which implies intent to influence control).

Related Party Transactions

• The Limited Power of Attorney dated July 16, 2015, between CVI Investments, Inc. and Heights Capital Management, Inc., establishes a formal relationship where Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and is authorized to enter into transactions on its behalf.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by institutional investors could be viewed positively, indicating institutional confidence in the company. It also clarifies the ownership structure and voting/dispositive power distribution among these large holders.

Key Dates

Recommendation

Keywords

Processa Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management, SEC Filing, Pharmaceuticals